Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KPG-818 |
Synonyms | |
Therapy Description |
KPG-818 targets cereblon (CRBN), a component of the CRL4-CRBN E3 ubiquitin ligase complex, and modifies its E3 ligase activity, which may lead to proteosomal degradation of T cell transcriptional repressors, potentially resulting in activation of immune response and decreased tumor cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KPG-818 | KPG818|KPG 818 | KPG-818 targets cereblon (CRBN), a component of the CRL4-CRBN E3 ubiquitin ligase complex, and modifies its E3 ligase activity, which may lead to proteosomal degradation of T cell transcriptional repressors, potentially resulting in activation of immune response and decreased tumor cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04283097 | Phase I | KPG-818 | Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects | Recruiting | USA | 0 |